Document Detail

Endogenous adenosine and coronary vasoconstriction in hypoperfused myocardium during exercise.
MedLine Citation:
PMID:  8287435     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: The coronary circulation has been shown to remain responsive to vasodilator and vasoconstrictor stimuli during myocardial ischaemia. The aim of this study was to investigate whether endogenous adenosine attenuates coronary vasoconstriction caused by the thromboxane A2 analogue, U46619. METHODS: Nine chronically instrumented dogs were studied during treadmill exercise in the presence of a coronary stenosis which resulted in distal left circumflex coronary artery hypoperfusion. Myocardial blood flow was assessed with radioactive microspheres during exercise prior to and during intracoronary infusion of U46619 (0.01 x min-1), in the absence and the presence of adenosine receptor blockade with intravenous 8-phenyltheophylline (5 and intracoronary adenosine deaminase (50 Distal coronary pressure was maintained constant during the control stenosis and the three interventions, at 49(SEM 3), 50(3), 50(3), and 50(3) mm Hg. RESULTS: During control exercise mean myocardial blood flow was 0.91(0.09) ml.min-1 x g-1 in the stenosis region and 2.54(0.28) in the normal region. With no change in distal coronary pressure, U46619 decreased mean myocardial blood flow to 0.70(0.10) ml.min-1 x g-1 (p < 0.05). Adenosine blockade alone decreased myocardial blood flow in the stenosis region to 0.60(0.07) ml.min-1 x g-1 (p < 0.05 v control stenosis), indicating that endogenous adenosine contributed to coronary vasodilatation in the ischaemic region. However, adenosine blockade did not augment the vasoconstriction in response to U46619 [mean myocardial blood flow 0.49(0.05) ml.min-1 x g-1], indicating that endogenous adenosine did not attenuate the vasoconstriction caused by U46619. CONCLUSIONS: Endogenous adenosine contributed to dilatation of resistance vessels in hypoperfused myocardium of exercising dogs in the absence as well as in the presence of U46619. However, endogenous adenosine did not attenuate the magnitude of the vasoconstrictor response to U46619. These findings are best explained by observations that thromboxane A2 and adenosine act on coronary vascular segments of different size.
D J Duncker; D D Laxson; P Lindstrom; R J Bache
Related Documents :
3664545 - Role of adenosine in mediating the coronary vasodilative response to acute hypoxia.
20980915 - Effects of selective cyclooxygenase-2 and non-selective cox inhibition on myocardial fu...
1555915 - Dilation of coronary microvessels by adenosine induced hypotension in dogs.
3711535 - Transient myocardial dysfunction during pharmacologic vasodilation as an index of reduc...
22157475 - Radial access in patients with st-segment elevation myocardial infarction undergoing pr...
19665865 - Left atrial reverse remodeling and cardiac resynchronization therapy for chronic heart ...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Cardiovascular research     Volume:  27     ISSN:  0008-6363     ISO Abbreviation:  Cardiovasc. Res.     Publication Date:  1993 Sep 
Date Detail:
Created Date:  1994-02-22     Completed Date:  1994-02-22     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0077427     Medline TA:  Cardiovasc Res     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1592-7     Citation Subset:  IM    
Department of Internal Medicine, University of Minnesota Medical School, Minneapolis 55455.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Adenosine / physiology*
Coronary Vessels / drug effects,  physiopathology*
Myocardial Contraction / drug effects
Myocardial Ischemia / physiopathology*
Physical Exertion / physiology*
Prostaglandin Endoperoxides, Synthetic / pharmacology
Regional Blood Flow / drug effects
Theophylline / analogs & derivatives,  pharmacology
Thromboxane A2 / analogs & derivatives,  pharmacology
Vasoconstriction / physiology*
Vasoconstrictor Agents / pharmacology
Reg. No./Substance:
0/Prostaglandin Endoperoxides, Synthetic; 0/Vasoconstrictor Agents; 57576-52-0/Thromboxane A2; 58-55-9/Theophylline; 58-61-7/Adenosine; 76898-47-0/15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 961-45-5/8-phenyltheophylline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cellular electrophysiology of WAY-123,398, a new class III antiarrhythmic agent: specificity of IK b...
Next Document:  Coordinate gene expression during neonatal rat heart development. A possible role for the myocyte in...